Inhalable formulation of fluticasone propionate and albuterol sulfate
AssigneeNorton (Waterford) Limited
InventorsBrian Paul O′Neill, Hardik Kirtikumar Shah, Julian Alexander Blair, Chris David Edlin, Shane Michael McKeon
Life of this patent
Estimating the term…
Abstract
This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
Claims3
A method for the treatment of acute exacerbations of asthma or COPD in a subject in need thereof, comprising administering to the subject pro re nata rescue medication of a dry powder inhalable formulation consisting of fluticasone propionate, albuterol sulfate and α-lactose monohydrate, wherein a total administered daily dose of fluticasone propionate does not exceed 1,000 μg.
Dependencies are inferred from the claim text.